Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Lung Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Neoplasm Metastasis 2 Cholangiocarcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Oligometastatic Prostate Cancer 1 Neoplasms 1 Metastatic Urothelial Cancer 1 Melanoma 1 Locally Advanced Pancreatic Cancer 1 Locally Advanced Cervical Cancer 1 Liver Neoplasms 1 Liposarcoma 1 Kidney Neoplasms 1 Gestational Trophoblastic Disease 1 Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Gemcitabine 83 Cisplatin 59 pembrolizumab 28 Paclitaxel 21 Nivolumab 21 Carboplatin 21 Cystectomy 20 Docetaxel 18 durvalumab 17 atezolizumab 17 Magnetic Resonance Spectroscopy 16 Specimen Handling 15 Radiotherapy 14 avelumab 13 Mitomycin 13 Sunitinib 12 Doxorubicin 12 Methotrexate 11 Fluorouracil 11 Vinblastine 10 Filgrastim 7 BCG Vaccine 7 Sorafenib 6 Ipilimumab 6 Immunoglobulin G 6 Disulfides 6 Biopsy 6 enfortumab vedotin 5 cabozantinib 5 Trastuzumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Urinary Bladder Neoplasms × zimberelimab × Clear all

NCT06528483 2024-07-30

preSAVE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡